E nrichment of apoplastic fluid with therapeutic recombinant protein for efficient biofarming

2017 ◽  
Vol 33 (3) ◽  
pp. 726-736 ◽  
Author(s):  
Aparajita Chatterjee ◽  
Narayan C. Das ◽  
Sumita Raha ◽  
Indu B. Maiti ◽  
Ankita Shrestha ◽  
...  
Keyword(s):  
Recombinant Protein ◽  
Apoplastic Fluid

Effectiveness of zona pellucida protein ZPB as an immunocontraceptive antigen

Reproduction ◽  
2000 ◽  
pp. 19-32 ◽  
Author(s):  
ML Martinez ◽  
JD Harris
Keyword(s):  
Menstrual Cycle ◽  
Recombinant Protein ◽  
Antibody Titre ◽  
Zona Pellucida ◽  
Protein A ◽  
Papio Cynocephalus ◽  
Cynomolgus Monkeys ◽  
Menstrual Cycles ◽  
Normal Menstrual Cycle

Immunization of female mammals with native zona pellucida (ZP) proteins is known to cause infertility. Since each human ZP protein is now available as a purified recombinant protein, is it possible to compare the immunocontraceptive potential of each ZP protein. A breeding study was conducted in cynomolgus monkeys (Macaca fasicularis) after immunization with recombinant human ZP (rhZP) proteins (ZPA, ZPB, ZPC) separately and in combinations. This study demonstrated that immunization with recombinant human ZPB (rhZPB) protein caused cynomolgus monkeys to become infertile for 9-35 months. A second study was conducted in baboons (Papio cynocephalus), which yielded a similar result. The baboons immunized with rhZPB became infertile for 9 to > 20 months. During the time of maximum antibody titre, some animals experienced disruption of the menstrual cycle, but eventually all of the animals resumed normal menstrual cycles. Control animals and animals immunized with other rhZP proteins all became pregnant before any of the rhZPB-treated animals. This is the first study in which a recombinant ZP protein has consistently induced infertility in a primate without permanent disruption of the normal menstrual cycle.

Use of Lectins for Analysis of Glycans in Recombinant Protein Biopharmaceuticals

2018 ◽  
pp. 707-709
Author(s):  
V. Monakhova ◽  
M. Sushkin ◽  
N. Pigareva ◽  
A. Simbirtsev
Keyword(s):  
Recombinant Protein

Immunoenhancement of Recombinant Neisseria meningitides PorB Protein on Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae Genetically Engineered Vaccines

2019 ◽  
Vol 26 (10) ◽  
pp. 776-784
Author(s):  
Rui Yang ◽  
Yu Tao ◽  
Gaojian Li ◽  
Jian Chen ◽  
Jianhong Shu ◽  
...  
Keyword(s):  
Recombinant Protein ◽  
Mycoplasma Hyopneumoniae ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Genetically Engineered ◽  
Porcine Circovirus ◽  
Practical Applications ◽  
Neisseria Meningitides ◽  
Short Period

Background:Porcine circovirus and Mycoplasma hyopneumoniae can cause respiratory diseases in pigs, which cause serious economic loss in the worldwide pig industry. Currently, these infections are mainly prevented and controlled by vaccination. The new vaccines on the market are mainly composed of subunits and inactivated vaccines but usually have lower antigenicity than traditional live vaccines. Thus, there is an increasing need to develop new adjuvants that can cause rapid and long-lasting immunity to enhance the antigenic efficacy for vaccines. Studies have shown that meningococcal porin PorB can act as a ligand to combine with Toll-like receptors to activate the production of immunological projections and act as a vaccine immunological adjuvant.Objective:In this article, we expressed and purified the recombinant PorB protein and verified its immunogenicity against porcine circovirus type 2 and Mycoplasma hyopneumoniae genetically engineered vaccine.Methods:In this article, we used prokaryotic expression to express and purify recombinant PorB protein, four different concentrations of PorB protein, Freund's adjuvant with two genetically engineered vaccines were combined with subcutaneous immunization of mice.Results:Our study shows that the appropriate dose of the recombinant protein PorB can enhance the levels of humoral and cellular responses induced by two genetically engineered vaccines in a short period of time in mice. The PorB adjuvant group may cause statistically higher antibody titers for both genetically engineered vaccines compared to Freund's commercial adjuvant (P<0.001).Conclusion:The recombinant protein PorB may be a good candidate adjuvant for improving the protective effect of vaccines against porcine circovirus type 2 and Mycoplasma hyopneumoniae, and the protein can be used for future practical applications.

Expression of hepatitis A virus cDNA in Escherichia coli: antigenic VP1 recombinant protein.

1987 ◽  
Vol 61 (11) ◽  
pp. 3645-3647 ◽  
Author(s):  
R Ostermayr ◽  
K von der Helm ◽  
V Gauss-Müller ◽  
E L Winnacker ◽  
F Deinhardt
Keyword(s):  
Escherichia Coli ◽  
Recombinant Protein ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Virus Cdna

scholarly journals Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models

2021 ◽  
Vol 22 (3) ◽  
pp. 1216
Author(s):  
Jordi Guiteras ◽  
Laura De Ramon ◽  
Elena Crespo ◽  
Nuria Bolaños ◽  
Silvia Barcelo-Batllori ◽  
...  
Keyword(s):  
Surface Plasmon Resonance ◽  
Recombinant Protein ◽  
Reperfusion Injury ◽  
Surface Plasmon ◽  
Plasmon Resonance ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Warm Ischemia ◽  
Solid Organ ◽  
Inflammatory Models

Many studies have shown both the CD28—D80/86 costimulatory pathway and the PD-1—PD-L1/L2 coinhibitory pathway to be important signals in modulating or decreasing the inflammatory profile in ischemia-reperfusion injury (IRI) or in a solid organ transplant setting. The importance of these two opposing pathways and their potential synergistic effect led our group to design a human fusion recombinant protein with CTLA4 and PD-L2 domains named HYBRI. The objective of our study was to determine the HYBRI binding to the postulated ligands of CTLA4 (CD80) and PD-L2 (PD-1) using the Surface Plasmon Resonance technique and to evaluate the in vivo HYBRI effects on two representative kidney inflammatory models—rat renal IRI and allogeneic kidney transplant. The Surface Plasmon Resonance assay demonstrated the avidity and binding of HYBRI to its targets. HYBRI treatment in the models exerted a high functional and morphological improvement. HYBRI produced a significant amelioration of renal function on day one and two after bilateral warm ischemia and on days seven and nine after transplant, clearly prolonging the animal survival in a life-sustaining renal allograft model. In both models, a significant reduction in histological damage and CD3 and CD68 infiltrating cells was observed. HYBRI decreased the circulating inflammatory cytokines and enriched the FoxP3 peripheral circulating, apart from reducing renal inflammation. In conclusion, the dual and opposite costimulatory targeting with that novel protein offers a good microenvironment profile to protect the ischemic process in the kidney and to prevent the kidney rejection, increasing the animal’s chances of survival. HYBRI largely prevents the progression of inflammation in these rat models.

scholarly journals Recombinant Protein Stability in Cyanobacteria

2021 ◽  
Vol 10 (4) ◽  
pp. 810-825
Author(s):  
Xianan Zhang ◽  
Nico Betterle ◽  
Diego Hidalgo Martinez ◽  
Anastasios Melis
Keyword(s):  
Recombinant Protein ◽  
Protein Stability

Ligation of a Synthetic Peptide to the N Terminus of a Recombinant Protein Using Semisynthetic Proteintrans-Splicing

2006 ◽  
Vol 45 (31) ◽  
pp. 5218-5221 ◽  
Author(s):  
Christina Ludwig ◽  
Martina Pfeiff ◽  
Uwe Linne ◽  
Henning D. Mootz
Keyword(s):  
Recombinant Protein ◽  
Synthetic Peptide ◽  
N Terminus
Sign in / Sign up

Export Citation Format

Share Document